HomeCompareNTUS vs ARCC

NTUS vs ARCC: Dividend Comparison 2026

NTUS yields 6.07% · ARCC yields 10.83%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NTUS wins by $5.3K in total portfolio value· pulled ahead in Year 2
10 years
NTUS
NTUS
● Live price
6.07%
Share price
$32.96
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.9K
Annual income
$893.24
Full NTUS calculator →
ARCC
Ares Capital Corporation
● Live price
10.83%
Share price
$17.73
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — NTUS vs ARCC

📍 NTUS pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNTUSARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NTUS + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NTUS pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NTUS
Annual income on $10K today (after 15% tax)
$515.78/yr
After 10yr DRIP, annual income (after tax)
$759.25/yr
ARCC
Annual income on $10K today (after 15% tax)
$920.47/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, NTUS beats the other by $758.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NTUS + ARCC for your $10,000?

NTUS: 50%ARCC: 50%
100% ARCC50/50100% NTUS
Portfolio after 10yr
$27.2K
Annual income
$447.20/yr
Blended yield
1.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

NTUS
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NTUS buys
0
ARCC buys
0
No recent congressional trades found for NTUS or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNTUSARCC
Forward yield6.07%10.83%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$29.9K$24.5K
Annual income after 10y$893.24$1.16
Total dividends collected$7.5K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: NTUS vs ARCC ($10,000, DRIP)

YearNTUS PortfolioNTUS Income/yrARCC PortfolioARCC Income/yrGap
1$11,307$606.80$11,381$541.46$74.00ARCC
2← crossover$12,739$641.21$12,622$284.25+$117.00NTUS
3$14,306$675.19$13,827$145.40+$479.00NTUS
4$16,017$708.64$15,062$73.47+$955.00NTUS
5$17,879$741.44$16,364$36.92+$1.5KNTUS
6$19,904$773.52$17,758$18.50+$2.1KNTUS
7$22,102$804.79$19,259$9.26+$2.8KNTUS
8$24,485$835.20$20,881$4.63+$3.6KNTUS
9$27,063$864.70$22,637$2.32+$4.4KNTUS
10$29,851$893.24$24,540$1.16+$5.3KNTUS

NTUS vs ARCC: Complete Analysis 2026

NTUSStock

Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers essential products used in the everyday operation of neonatal intensive care unit (NICU); balance assessment systems to evaluate patients with balance disorders; and NICVIEW, a live streaming video for families with babies in the NICU. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was formerly known as ALGOTEK Instruments, Inc. and changed its name to Natus Medical Incorporated in September 1988. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Middleton, Wisconsin.

Full NTUS Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this NTUS vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NTUS vs SCHDNTUS vs JEPINTUS vs ONTUS vs KONTUS vs MAINNTUS vs HTGCNTUS vs GBDCNTUS vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.